IL-17RB, commonly referred to as Interleukin-17 receptor B, is a transmembrane protein receptor from the IL-17 receptor family. It serves as a receptor for certain cytokines, such as IL-17B and IL-17E, which are involved in inflammation and tissue repair. Several illnesses, including cancer, inflammatory bowel disease, and asthma, have been related to abnormal IL-17RB expression. Understanding the function and regulation of IL-17RB expression can provide insights into the development of new treatments for these diseases.
Its Gene ID: 55540, UniProtKB ID: Q9NRM6, and OMIM ID: 605458.
IL-17RB is expressed in various tissues throughout the body. It is commonly found in the lungs, where it regulates immune responses and inflammation. Additionally, elevated IL-17RB expression has been detected in the skin, where it is involved in skin inflammation and repair processes. In the gastrointestinal tract, IL-17RB is expressed in the mucosal lining and has been linked to inflammatory bowel illnesses including Crohn's disease. Furthermore, IL-17RB expression has been observed in tissues like the liver, kidney, and brain, indicating its diverse roles in immune regulation and tissue homeostasis.
Fig.1 IL-17B induces the expression of IL-17RB.1
IL-17RB is a receptor for IL-17B and IL-17E. Activation of IL-17RB leads to the activation of the canonical NK-κB pathway as well as ERK, JNK, p38, and MAPK, promoting inflammation and immune responses.
When IL-17B activates IL-17RB, it recruits immune cells and produces pro-inflammatory cytokines such as IL-6 and IL-8. This pathway is involved in a variety of inflammatory disorders. Targeting the IL-17B/RB pathway holds potential for developing novel therapeutic strategies for treating these inflammatory diseases.
Several studies over the last decade have emphasized the possible relevance of the IL-17B/IL-RB pathway in cancer genesis and progression. High expression of IL-17B and IL-17RB has been observed in various tumor types, including breast, lung, colorectal, and pancreatic cancers. Activation of this pathway promotes tumor growth and metastasis by stimulating angiogenesis, enhancing tumor cell survival, and suppressing anti-tumor immune responses. Additionally, IL-17B/IL-17RB signaling induces the production of pro-inflammatory cytokines and chemokines, creating a tumor-promoting microenvironment. Targeting this pathway holds promise for developing novel anti-cancer therapies and improving patient outcomes in tumors where IL-17B/IL-17RB signaling is dysregulated.
The development of a neutralizing antibody targeting IL-17RB holds great therapeutic potential in treating inflammatory diseases and cancers. By specifically binding to IL-17RB, this antibody can block the receptor's activation by IL-17B and IL-17E, thereby inhibiting downstream signaling pathways involved in inflammation and tumor progression. In a mouse xenograft model, studies have found that treatment with anti-IL-17RB monoclonal antibodies can delay the malignancy of IL-17RB-expressing pancreatic cancer cells, block tumor metastasis, and significantly extend the survival time of animals.
Fig.2 Targeting-IL-17RB could inhibit cancer stemness activity.2
Creative Biolabs provides different types of high-specificity anti-IL-17RB antibody products. These antibodies are recombinantly expressed and can be employed in different applications including ELISA and IHC staining.
Anti-IL17RB Neutralizing Antibody (V3S-0522-YC2362) (CAT#: V3S-0522-YC2362)
Target: IL17RB
Host Species: Mouse
Target Species: Human, Mouse,
Application: WB,DB,ELISA,FC,Inhib,FuncS,
Anti-IL17RB Neutralizing Antibody (V3S-0622-YC274) (CAT#: V3S-0622-YC274)
Target: IL17RB
Host Species: Mouse
Target Species: Human,
Application: ELISA,IHC,FC,Neut,
Human Anti-IL17RB Neutralizing Antibody (V3S-0622-YC275) (CAT#: V3S-0622-YC275)
Target: IL17RB
Host Species: Human
Target Species: Human,
Application: ELISA,IHC,FC,Neut,
